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Platelet Activation and Myocardial Infarction
in Patients With Pneumonia
Are Statins the Answer?We thank Dr. Gavrillaki and colleagues for the com-
ments related to our recent paper (1) demonstrating a
signiﬁcant association between in vivo platelet acti-
vation and myocardial infarction (MI) in 278 patients
affected by community-acquired pneumonia (CAP)
and suggesting a potential role for platelets in
precipitating coronary ischemia.
Dr. Gavrillaki and colleagues raise some issues that
need to be addressed. The authors question the pu-
tative interplay between infections and MI overall
because interventional trials with antibiotics failed to
show a reduction of MI. However, trials with antibi-
otics have serious clinical and methodological limi-
tations regarding dosages of the antibiotics, wide
variation in sample size and follow-up, and limited
use of antibiotics (essentially macrolides and ﬂuo-
roquinolone) (2). Furthermore, interventional trials
with antibiotics have been performed in patients
with stable or acute coronary heart disease on the
assumption that microorganisms, in particular Chla-
mydia pneumoniae, are implicated in atherosclerosis
initiation and progression (2).
Hence, it is methodologically inappropriate to
extrapolate from these ﬁndings that infections can-
not precipitate MI because these clinical settings are
different in terms of clinical course, concomitant
treatment, and very likely, mechanism of disease
from CAP-related MI. In this context, it is clinically
relevant that pneumonia severity score was a
strong predictor of MI, indicating that the severity of
infection and/or inﬂammation plays a key role in
favoring myocardial ischemia. Platelet activation
may be one mechanism through which CAP pre-
cipitates MI via a process of coronary thrombosis
and/or vasoconstriction. We don’t have conclusive
data on this issue, but it is interesting to underscorethat most patients with CAP disclosed non–ST-
segment elevation MI, indicating that type II MI and,
therefore, coronary vasoconstriction might have an
important role in favoring myocardial ischemia.
We agree with the authors that the concomitant
presence of cardiovascular disease or atherosclerotic
risk factors could account for platelet activation
detected at admission, but its signiﬁcant reduction,
observed at discharge, points to a role of CAP in
favoring platelet activation. The mechanism(s) ac-
counting for CAP-related platelet activation were not
investigated in the study and consequently may be
only a matter of speculation. Analysis of more
sophisticated markers of platelet activation will
certainly help to provide more insight into the role
of platelets as a determinant of myocardial ischemia
in pneumonia. However, we believe that at this
moment, it is more crucial to know whether platelet
activation represents a mere epiphenomenon of CAP
or has a role in triggering coronary thrombosis
and/or vasoconstriction. Thus, interventional trials
with aspirin or other antiplatelet drugs could be of
interest to investigate whether platelets actually
have a role in precipitating MI in patients with
pneumonia.
Interestingly, Dr. Khan and colleagues, in their
letter, suggest that statins may be an intriguing
alternative because they possess antiplatelet activity,
and a recent meta-analysis demonstrated a potential
role of statins in reducing CAP-related mortality (3).
We agree with this hypothesis because statins
disclose an early and late antiplatelet effect, which is
mediated by down-regulation of Nox2-derived
oxidative stress and lipid-lowering activity, respec-
tively (4). Nox2 down-regulation may be of interest
because in patients with CAP Nox2, the most
important cellular producer of oxygen free radicals,
is up-regulated and associated with myocardial
damage and ischemia (5). Furthermore, statins
amplify the platelet response to aspirin by reducing
platelet eicosanoid formation, namely isoprostanes
and thromboxane A2, and could, in turn, be useful in
case of incomplete COX1 inhibition by aspirin (4).
Hence, statins may be tested as an alternative to
aspirin or on top of aspirin to assess whether they
are able to reduce cardiac complications in patients
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REPLY: Platelets Interplay Between Pneumonia andCardiovascular Events
Establishing a Link?We appreciate the interest by Dr. Gavrillaki and col-
leagues in our editorial and their insightful comments.
First of all, Dr. Gavrillaki and colleagues indicate
that we support the infection hypothesis for athero-
sclerosis. We do not support such hypothesis, and
thus, this afﬁrmation was not stated in our editorial.
We do believe the role of inﬂammatory processes (not
necessarily infective) in the genesis and progression
of atherosclerosis (1). In fact, a variety of systemic
proinﬂammatory conditions increase the risk of
atherosclerotic cardiovascular events, including rhe-
umatoid arthritis, systemic lupus erythematosus,
or psoriatic arthritis (2). Furthermore, atherosclerosis
is aggravated by systemic inﬂammation of any etiol-
ogy, as the one seen after myocardial infarction (MI)
(3). It is in this context of atherosclerosis as asystemic inﬂammatory disease (but never of
atherosclerosis as caused by microorganisms) where
our comments about the pathophysiological link
between community-acquired pneumonia (CAP) and
MI should be placed. It is the systemic inﬂammatory
response originated by CAP and inﬂuenza infection
(and not the microorganism per se) that most likely
aggravates atherosclerosis burden and contribute to
the destabilization of atheroma plaques, thus
increasing the risk of MI. In fact, we do agree with
Dr. Gavrillaki and colleagues in the microorganism
theory having been refuted long ago (4).
Second, Dr. Gavrillaki and colleagues consider the
increased platelet activation in CAP patients devel-
oping MI because of the comorbidities of those pa-
tients, and thus already present even before the CAP.
Notwithstanding, Cangemi et al. (5) adjust in the
multivariate analysis for those baseline (i.e., pre-CAP)
comorbidities (age, sex, body mass index, diabetes,
hypertension, renal failure, previous MI or stroke,
peripheral artery disease), and they also test for
collinearity, so we can conclude that enhanced
platelet reactivity in CAP patients is independently
associated with MI even after adjusting for those
baseline comorbidities. That platelet aggregation is a
risk marker or a risk factor is a different story that
cannot be demonstrated statistically, only by trial
evidence, demonstrating that altering the risk factor
(platelet aggregation in CAP) changes the prognosis
(MI).
Finally, we do agree with Dr. Gavrillaki and col-
leagues regarding that platelet reactivity, not aggre-
gation, was assessed in the study by Cangemi et al.
(5). As they suggest, the monocyte–platelet aggre-
gates (MPA) are one marker of platelet activation that
could shed additional information on the link be-
tween platelet activation in CAP and MI. However,
heterotypic platelet aggregation (of which MPA is the
prime example) is not the only parameter to assess/
study platelet activation. Other markers such as ho-
motypic platelet aggregation (by light-transmission
aggregometry) or soluble serum markers (such as
the P-Selectin, CD40L, or TXB2 that Cangemi et al. [5]
used) are universally established/accepted, so the
choice of a speciﬁc marker does not change the
hypothesis-generating message of this article. Future
studies will undoubtedly analyze additional markers
of platelet activation (including MPA) to proﬁle in
depth the postulated mechanistic role of increased
platelet reactivity in MI incidence among CAP
patients.
